2017
DOI: 10.1002/jcp.26041
|View full text |Cite
|
Sign up to set email alerts
|

Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress

Abstract: Colorectal cancer (CC) is often diagnosed at a late stage when tumor metastasis may have already occurred. Current treatments are often ineffective in metastatic disease, and consequently late diagnosis is often associated with poor outcomes in CC. Alternative strategies are therefore urgently required. An interaction between epithelial cancer cells and their tissue microenvironment is a contributor to metastasis, and therefore recent studies are beginning to focus on the properties of the tumor microenvironme… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
27
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
9

Relationship

4
5

Authors

Journals

citations
Cited by 42 publications
(27 citation statements)
references
References 83 publications
0
27
0
Order By: Relevance
“…Colorectal cancer (CRC) is the third most common type of cancer and fourth leading cause of cancer death in the world as about 690,000 people annually die for this disease (Arnold et al, 2017). Clinically, chemotherapy and radiation are commonly used before or after surgery, even so 40% of all patients develop metastasis and presented recidives (Bahrami et al, 2018). CRC is classified by its clinicopathological characteristics, but clinical outcomes and drugs response, molecular characteristics and prognosis are uncertain and heterogeneous (Rodriguez-Salas et al, 2017).…”
Section: Introductionmentioning
confidence: 99%
“…Colorectal cancer (CRC) is the third most common type of cancer and fourth leading cause of cancer death in the world as about 690,000 people annually die for this disease (Arnold et al, 2017). Clinically, chemotherapy and radiation are commonly used before or after surgery, even so 40% of all patients develop metastasis and presented recidives (Bahrami et al, 2018). CRC is classified by its clinicopathological characteristics, but clinical outcomes and drugs response, molecular characteristics and prognosis are uncertain and heterogeneous (Rodriguez-Salas et al, 2017).…”
Section: Introductionmentioning
confidence: 99%
“…These are the 6 hallmarks of malignancy. 13 In association with CD 26 with dipeptidyl peptidase IV activity, ADA exists on the cell surface and intracellularly as well, without own transmembrane domain. 14 Solid tumors release adenosine due to adenine nucleotide degradation which is caused by severe hypoxia and necrosis which in turn is caused by aggressive growth of the tumor.…”
Section: Discussionmentioning
confidence: 99%
“…13.63%) patients were in stage I, 31 (35.22%) patients in stage II, 27 (30.68%) patients in stage III and 9 (10.22%) patients in stage IV of the disease. Mean ADA levels in stage I, II, III and IV were found to be 23.88 IU/l, 27.68 IU/l, 30.50 IU/l and 41.88 IU/l respectively, which are statistically significant for respective stage of the malignancy.…”
mentioning
confidence: 97%
“…As the 'residence niche' of cancer cells, the composition and structure of the tumor microenvironment not only affects the bio-behavior, but also determines the survival and elimination of tumor cells (1)(2)(3). Targeting the tumor microenvironment by remodeling its components and construction could be a useful a strategy to treat and prevent cancer (4).…”
Section: Introductionmentioning
confidence: 99%